{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:28:13Z","timestamp":1740806893152,"version":"3.38.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.7759\/cureus.79811","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:26:37Z","timestamp":1740738397000},"source":"Crossref","is-referenced-by-count":0,"title":["Paraneoplastic Immune Thrombocytopenia in Estrogen Receptor (ER)-Positive\/Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer: Clinical Implications and Therapeutic Strategies"],"prefix":"10.7759","author":[{"given":"Rita","family":"Antunes Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana R","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gon\u00e7alo","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alda","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27819","article-title":"Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years","volume":"119","author":"Tevaarwerk AJ","year":"2013","unstructured":"Tevaarwerk AJ, Gray RJ, Schneider BP, et al.. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013, 119:1140-8. 10.1002\/cncr.27819","journal-title":"Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh MA","year":"1999","unstructured":"Cobleigh MA, Vogel CL, Tripathy D, et al.. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999, 17:2639-48. 10.1200\/JCO.1999.17.9.2639","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al.. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344:783-92. 10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2005.n.026","article-title":"Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab","volume":"6","author":"Mass RD","year":"2005","unstructured":"Mass RD, Press MF, Anderson S, et al.. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005, 6:240-6. 10.3816\/CBC.2005.n.026","journal-title":"Clin Breast Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.03.007","article-title":"Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics","volume":"23","author":"O'Shaughnessy J","year":"2023","unstructured":"O'Shaughnessy J, Gradishar W, O'Regan R, Gadi V. Risk of recurrence in patients with HER2+ early-stage breast cancer: literature analysis of patient and disease characteristics. Clin Breast Cancer. 2023, 23:350-62. 10.1016\/j.clbc.2023.03.007","journal-title":"Clin Breast Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer","volume":"372","author":"Swain SM","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, et al.. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015, 372:724-34. 10.1056\/NEJMoa1413513","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt460.76","article-title":"27 cases of paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"24","author":"Jo T","year":"2013","unstructured":"Jo T, Okamoto Y, Tsukamoto T, et al.. 27 cases of paraneoplastic autoimmune thrombocytopenia in solid tumors. Ann Oncol. 2013, 24:10.1093\/annonc\/mdt460.76","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.02.004","article-title":"Paraneoplastic autoimmune thrombocytopenia in solid tumors","volume":"81","author":"Krauth MT","year":"2012","unstructured":"Krauth MT, Puthenparambil J, Lechner K. Paraneoplastic autoimmune thrombocytopenia in solid tumors. Crit Rev Oncol Hematol. 2012, 81:75-81. 10.1016\/j.critrevonc.2011.02.004","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3:3829-66. 10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.08.006","article-title":"Immune thrombocytopenia in lymphoproliferative disorders","volume":"23","author":"Visco C","year":"2009","unstructured":"Visco C, Rodeghiero F. Immune thrombocytopenia in lymphoproliferative disorders. Hematol Oncol Clin North Am. 2009, 23:1261-74. 10.1016\/j.hoc.2009.08.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-010-1319-z","article-title":"Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature","volume":"122","author":"Puthenparambil J","year":"2010","unstructured":"Puthenparambil J, Lechner K, Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010, 122:229-36. 10.1007\/s00508-010-1319-z","journal-title":"Wien Klin Wochenschr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2019.413","article-title":"Thrombocytopenia in solid tumors: prognostic significance","volume":"13","author":"Ghanavat M","year":"2019","unstructured":"Ghanavat M, Ebrahimi M, Rafieemehr H, Maniati M, Behzad MM, Shahrabi S. Thrombocytopenia in solid tumors: prognostic significance. Oncol Rev. 2019, 13:10.4081\/oncol.2019.413","journal-title":"Oncol Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/344536-paraneoplastic-immune-thrombocytopenia-in-estrogen-receptor-er-positivehuman-epidermal-growth-factor-receptor-2-her2-positive-advanced-breast-cancer-clinical-implications-and-therapeutic-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T10:26:40Z","timestamp":1740738400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/344536-paraneoplastic-immune-thrombocytopenia-in-estrogen-receptor-er-positivehuman-epidermal-growth-factor-receptor-2-her2-positive-advanced-breast-cancer-clinical-implications-and-therapeutic-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.79811","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}